| 7.05 0.44 (6.66%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.43 | 1-year : | 9.84 |
| Resists | First : | 7.21 | Second : | 8.43 |
| Pivot price | 6.57 |
|||
| Supports | First : | 6 |
Second : | 5.25 |
| MAs | MA(5) : | 6.53 |
MA(20) : | 6.48 |
| MA(100) : | 5.97 |
MA(250) : | 7.86  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 64 |
D(3) : | 56.1 |
| RSI | RSI(14): 66.4 |
|||
| 52-week | High : | 13.22 | Low : | 4.48 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RXST ] has closed below upper band by 14.7%. Bollinger Bands are 8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.7 - 6.73 | 6.73 - 6.75 |
| Low: | 6.2 - 6.23 | 6.23 - 6.26 |
| Close: | 6.55 - 6.61 | 6.61 - 6.65 |
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Wed, 26 Aug 2026
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference - The Manila Times
Wed, 26 Aug 2026
RxSight management is scheduled to speak in Boston on Sept. 9 - Stock Titan
Tue, 25 Aug 2026
RxSight (NASDAQ: RXST) refreshes documents for option exchange - Stock Titan
Thu, 13 Aug 2026
Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery? - Yahoo Finance
Thu, 06 Aug 2026
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside - Yahoo Finance
Wed, 05 Aug 2026
New RxSight lenses are intended to reduce post-surgery office visits - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 42 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 100.5 (%) |
| Shares Short | 4,060 (K) |
| Shares Short P.Month | 5,510 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.32 |
| Profit Margin | -36.8 % |
| Operating Margin | -40.9 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -17.4 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 2.37 |
| Sales Per Share | 3.06 |
| EBITDA (p.s.) | -1.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -6.19 |
| PEG Ratio | 0 |
| Price to Book value | 1.11 |
| Price to Sales | 2.29 |
| Price to Cash Flow | -12.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|